Lilly Scoops up Adverum for $261M, with CVR and Loan

/ Bharat Kirthivasan

Adverum Biotechnologies (ADVM:NASDAQ) is being acquired by Eli Lilly and Company for $261M.

While the acquisition proposes a transfer of $261M from Lilly to Adverum’s stockholders, it is structured through a milestone payment and a bridge-loan.

Payment Snapshot

Upfront – $3.56/share
CVR – max $8.91/share contingent upon FDA approval and target sales of Ixo-vec.
Bridge Loan – Lilly will lend Adverum $65M before deal completion.

What Adverum does

Therapeutic focus: Restoring vision and preventing blindless in ocular diseases.
Modality: Intra-vitreal single-injection gene therapy
Primary asset: Ixo-vec (single-injection gene therapy to treat wet-age-related macular degeneration (wAMD).

Adverum’s Pre-Deal Financial Status

Equity value (market cap): $85M
Cash & Short-term Investments: $44M
Total Debt: $92M
Adverum’s cash was to run out in October 2025, which makes this deal fortuitous as it will allow Ixo-vec (Adverum’s promising asset) to proceed through its clinical trial.

An alternative view is that Lilly is buying Adverum at a discount. The upfront payment ($3.56/share) is lower than Adverum’s pre-deal stock price (Lowest price on 10/24/2025 = $3.98/share).

CVR Details

  • ≤ $1.78/share: when Ixo-vec gets U.S. approval of Ixo-vec, if it occurs prior to 7 years after deal closing.
  • ≤ $7.13/share: when net annual sales (worldwide) of Ixo-vec reach $1B, if it occurs prior to 10 years after deal closing.

Loan through Promissory Note

Adverum signs a Promissory note with Lilly, which allows them to borrow $65M (in 4 installments) from Lilly before deal completion.
Loan Security: All of Adverum’s assets (including its intellectual property).
If this deal falls through, Lilly may demand immediate repayment of the entire loan.

References

Leave a comment